Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Ceritinib - Novartis

Next Previous
Drug Profile

Ceritinib - Novartis

Alternative Names: Jikadia; LDK-378; NVP-LDK 378; NVP-LDK378-NX; Zykadia

Latest Information Update: 11 Dec 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Novartis
  • Developer H. Lee Moffitt Cancer Center and Research Institute; Novartis; University of Texas Southwestern Medical Center
  • Class Antineoplastics; Diamines; Piperidines; Pyrimidines; Small molecules; Sulfones
  • Mechanism of Action Anaplastic lymphoma kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Non-small cell lung cancer
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Non-small cell lung cancer
  • Phase II Gastrointestinal cancer; Haematological malignancies; Solid tumours; Thyroid cancer
  • No development reported Malignant melanoma

Most Recent Events

  • 10 Nov 2023 Novartis completes a phase III ASCEND-5 trial for Non-small cell lung cancer (late-stage disease, Metastatic-disease, second-line or greater therapy) in USA, Belgium, Canada, France, Germany, Hong Kong, Ireland, Israel, Italy, Japan, South Korea, Lebanon, Netherlands, Portugal, Russia, Switzerland, Turkey, United Kingdom, Singapore, Spain (PO) (NCT01828112)
  • 28 Aug 2022 No recent reports of development identified for clinical-Phase-Unknown development in Non-small-cell-lung-cancer(Late-stage disease, Second-line therapy or greater) in Jordan (PO, Capsule)
  • 28 Aug 2022 No recent reports of development identified for clinical-Phase-Unknown development in Non-small-cell-lung-cancer(Late-stage disease, Second-line therapy or greater) in Philippines (PO, Capsule)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top